No Result
View All Result
Success American Investors
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Success American Investors
No Result
View All Result
Home Investing

Fevertree taps Molson Coors with £71m stake sale to fuel US growth

by
January 31, 2025
in Investing
0
Fevertree taps Molson Coors with £71m stake sale to fuel US growth
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Premium mixer maker Fevertree has secured a deal with US beverage giant Molson Coors that will see the latter take an 8.5 per cent stake in the British-based company for £71 million, or 654.2p per share.

The move, underpinned by an exclusive licensing agreement, aims to boost Fevertree’s sales, distribution and production footprint across the United States.

Shares in Fevertree, which floated at just 134p in 2014, leapt by 20.2 per cent on Thursday to close at 791p—though this remains far short of the record high of £39.56 set in September 2018. Proceeds from the new stake sale will be returned to Fevertree shareholders through a buyback programme.

Molson Coors, the Chicago-headquartered name behind Carling and Doom Bar, has been broadening its non-alcoholic portfolio in response to declining beer sales, with shipments of US beer last year hitting their lowest levels since the 1990s. “This is a meaningful step towards becoming a total beverage company,” said Gavin Hattersley, Molson Coors’ chief executive, highlighting the opportunity to diversify into premium mixers.

Fevertree founder and CEO Tim Warrillow called the deal a “transformational step”, adding that it reflects growing demand for higher-quality mixers across multiple drink categories in the US, now Fevertree’s biggest market by revenue.

Under the agreement, Molson Coors will leverage its extensive American sales and distribution network, as well as operational scale, to amplify Fevertree’s presence. The new partnership is expected to improve the mixer maker’s cash conversion in the US, reducing working capital needs.

Some analysts, such as Fintan Ryan at Goodbody, believe relinquishing direct operational control could prove a strategic trade-off. However, Matthew Webb of Investec and Anubhav Malhotra at Panmure Liberum suggest that the deal not only unlocks fresh capital returns for Fevertree shareholders but also secures Molson Coors as a potential long-term acquirer of the brand.

Meanwhile, Fevertree reported a modest 1 per cent increase in full-year group revenues to £367.9 million and signalled a likely dip to low single-digit revenue growth in 2025 as it transitions its US operations to Molson Coors.

This tie-up follows other high-profile industry collaborations, including Carlsberg’s recent $4.2 billion purchase of Britvic, the British drinks maker behind Robinsons and J2O, as brewers and beverage groups continue to expand into alternative and soft-drinks markets.

Read more:
Fevertree taps Molson Coors with £71m stake sale to fuel US growth

Previous Post

KAI Conversations Receives Successful Funding Round and ScaleUp Group Spotlights Industry Event Participation

Next Post

“Discover the Coastal Heroes: Mangroves Featured on World Wetlands Day”

Next Post

“Discover the Coastal Heroes: Mangroves Featured on World Wetlands Day”

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest
Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

February 14, 2024

Last Day to Give in 2023!

December 31, 2023
Idaho Bucks Managed Care Trend

Idaho Bucks Managed Care Trend

December 5, 2023

The Producer Price Index

September 9, 2023
Randomized Controlled Trials of Medicare and Medicaid, Please

Randomized Controlled Trials of Medicare and Medicaid, Please

0

0

0

0
Randomized Controlled Trials of Medicare and Medicaid, Please

Randomized Controlled Trials of Medicare and Medicaid, Please

July 21, 2025
China Shocked? Hard Hit Metropolitan Statistical Areas Have Performed Well Economically Since 2000

China Shocked? Hard Hit Metropolitan Statistical Areas Have Performed Well Economically Since 2000

July 21, 2025
Trump’s first six months in office spark surge in Bitcoin millionaires, Finbold research reveals

Trump’s first six months in office spark surge in Bitcoin millionaires, Finbold research reveals

July 21, 2025

FreeBalance Chosen by Bougainville for Modernizing Public Financial Management with Digital Transformation

July 21, 2025

Recent News

Randomized Controlled Trials of Medicare and Medicaid, Please

Randomized Controlled Trials of Medicare and Medicaid, Please

July 21, 2025
China Shocked? Hard Hit Metropolitan Statistical Areas Have Performed Well Economically Since 2000

China Shocked? Hard Hit Metropolitan Statistical Areas Have Performed Well Economically Since 2000

July 21, 2025
Trump’s first six months in office spark surge in Bitcoin millionaires, Finbold research reveals

Trump’s first six months in office spark surge in Bitcoin millionaires, Finbold research reveals

July 21, 2025

FreeBalance Chosen by Bougainville for Modernizing Public Financial Management with Digital Transformation

July 21, 2025

Disclaimer: SuccessAmericanInvestors.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 SuccessAmericanInvestors. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 SuccessAmericanInvestors. All Rights Reserved.